A new pilot program uses regulated prediction markets and independent data verification to establish public probabilities for ...

Phase 1/2 DELIVER data demonstrated statistically significant dystrophin expression, functional improvements, and a favorable safety profile with z-rostudirsen.

Most obesity drugs do not improve quality of life or heart health, according to a review published online July 8 in The BMJ.

Higher diagnostic accuracy reported for dementia experts vs primary care doctors before disclosure of test results, but not after.

The APPLAUSE-IgAN study met its final analysis primary endpoint, demonstrating a significantly slower rate of kidney function decline with iptacopan compared with placebo. The Food and Drug ...

Following a manufacturing-related Complete Response Letter in June 2026, the resubmitted application for the once-monthly subcutaneous depot is back under FDA review.

Most ION events occurred in men, patients 50 years or older, with minimal risk seen in women, patients younger than 50 years ...

Shionogi’s application seeks approval for pediatric patients (from 26 weeks gestational age to under 18 years) based on data from 154 patients across three phase 2 trials.

By neutralizing circulating dipeptidyl peptidase 3, the novel monoclonal antibody aims to reverse RAAS dysregulation and stabilize cardiovascular hemodynamics.

Credit: Merck. Supported by the phase 3 CORALreef program, Merck’s once-daily oral macrocyclic peptide offers a non-injectable PCSK9-targeting pathway to significantly clear LDL-C in adults. Lipfendra ...